Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Raises Price Target to $84
Benzinga Newsdesk 1 year ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $78 to $84.
Guggenheim analyst Eddie Hickman maintains Tarsus Pharmaceuticals (NASDAQ:TARS) with a Buy and raises the price target from $78 to $84.